View Older Stories View More Recent Stories

May 24, 2018 07:34PM Eisai And Merck Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib in First-Line Unresectable Hepatocellular Carcinoma
May 24, 2018 07:05AM Foundation Medicine (FMI) Reports Immuno-Oncology Companion Diagnostics Collaboration with Merck (MRK)
May 23, 2018 06:46AM Merck's (MRK) KEYTRUDA Significantly Improved OS and PFS as First-Line Treatment for NSCLC in Pivotal Phase 3 KEYNOTE-407 Trial
May 23, 2018 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment for Squamous Non-Small Cell Lung Cancer (NSCLC) in Pivotal Phase 3 KE
May 22, 2018 02:21PM Merck Announces Third-Quarter 2018 Dividend
May 16, 2018 05:05PM New Data from Merck’s Leading Immuno-Oncology Clinical Development Program in Over 25 Tumor Types to Be Presented at 2018 ASCO Annual Meeting
May 8, 2018 06:50AM AstraZeneca (AZN), Merck (MRK) LYNPARZA Tablets Receive EU Approval for Treatment of Platinum-Sensitive Relapsed Ovarian Cancer
May 8, 2018 06:45AM LYNPARZA® (olaparib) Tablets Receive EU Approval for the Treatment of Platinum-Sensitive Relapsed Ovarian Cancer
May 7, 2018 07:03AM Veeva Announces Merck’s Expanded Use of Veeva CRM for Latin America and Asia Pacific
May 3, 2018 04:55PM Moderna and Merck (MRK) Expand mRNA Cancer Vaccines Pact
May 3, 2018 04:15PM Moderna and Merck Expand mRNA Cancer Vaccines Collaboration
May 3, 2018 06:46AM Merck (MRK) KEYNOTE-407 Trial Met Pre-specified Secondary Endpoint
May 3, 2018 06:45AM Merck Provides Update on KEYNOTE-407 Trial
May 1, 2018 06:45AM Merck Announces First-Quarter 2018 Financial Results
Apr 30, 2018 06:46AM Merck (MRK) Announces FDA Granted Priority Review to its sBLA for KEYTRUDA in Combination with Pemetrexed and Platinum Chemotherapy as First-Line Treatment of Metastatic Nonsquamous NSCLC
Apr 30, 2018 06:45AM FDA Grants Priority Review to Merck’s sBLA for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy Based on Results from Phase 3 KEYNOTE-189 Trial as Firs
Apr 23, 2018 04:35PM Merck (MRK) Reports EMA Validation of Type II Variation for KEYTRUDA (pembrolizumab) in Combination with Pemetrexed (ALIMTA) and Platinum Chemotherapy
Apr 23, 2018 04:30PM European Medicines Agency Validates Type II Variation for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy as First-Line Therapy in Metastatic N
Apr 17, 2018 08:35AM Merck (MRK) Says It's Beginning Two Phase 3 Studies of PCV-15 (V114), Its Investigational Pneumococcal Disease Vaccine
Apr 17, 2018 08:30AM Merck Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease Vaccine
Apr 16, 2018 09:35AM Merck (MRK) Announces Results from KEYNOTE-189, a Pivotal Phase 3 Trial Evaluating KEYTRUDA (anti-PD-1 therapy) in Combination with Pemetrexed (ALIMTA) and Cisplatin
Apr 16, 2018 09:30AM Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed (ALIMTA®) and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as First-Line Treatment for Advanced Nonsqu
Apr 16, 2018 05:58AM AstraZeneca (AZN) & Merck (MRK) Report Overall Survival Data for LYNPARZA (olaparib) in gBRCA-Mutated HER2-Negative Metastatic Breast Cancer
Apr 16, 2018 05:52AM Merck (MRK) Reports Results from Phase 3 EORTC1325/KEYNOTE-054 Trial Investigating KEYTRUDA as Adjuvant Therapy
Apr 15, 2018 04:50PM Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-mutated HER2-Negative Metastatic Breast Cancer Presented at AACR
Apr 15, 2018 09:30AM Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Disease Recurrence or Death by More than 40 Percent Compared to Placebo as Adjuvant Therapy in Resected, High-Risk Stage III Melanoma
Apr 9, 2018 06:45AM Merck (MRK) Says KEYTRUDA Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-042 Study
Apr 9, 2018 06:45AM KEYTRUDA® (pembrolizumab) Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-042 Study, Significantly Improving OS as First-Line Therapy in Locally Advanced or Metastatic NSCLC Patients Expressing P
Apr 6, 2018 07:32AM Incyte (INCY) Phase 3 ECHO-301 Study Didn't Meet Primary Endpoint
Apr 6, 2018 07:30AM Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA® (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma
Apr 3, 2018 06:02AM Merck (MRK) Reports EMA Acceptance of Regulatory Submission for LYNPARZA (olaparib) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer
Apr 3, 2018 06:00AM The European Medicines Agency Accepts Regulatory Submission for LYNPARZA® (olaparib) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer
Apr 2, 2018 06:45AM Merck to Hold First-Quarter 2018 Sales and Earnings Conference Call on May 1
Mar 23, 2018 06:25AM Eisai, Merck (MRK) Announce Anticancer Agent LENVIMA was Approved for Additional Indication of HCC in Japan
Mar 23, 2018 06:00AM Anticancer Agent LENVIMA® (lenvatinib mesylate) Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan, First Approval Worldwide for LENVIMA for HCC
Mar 21, 2018 06:24AM Merck's (MRK) MSD Animal Health Receives Positive Opinion from EMA for BRAVECTO Plus Spot-on Solution for Cats
Mar 21, 2018 02:00AM MSD Animal Health Receives Positive Opinion from European Medicines Agency for BRAVECTO® Plus (fluralaner plus moxidectin) Spot-on Solution for Cats
Mar 20, 2018 04:05PM Merck Announces Appointment of Jennifer Zachary as General Counsel
Mar 14, 2018 06:30PM First-Line Lung Cancer Data and Other New Research from Merck’s Broad Oncology Program to be Presented at AACR Annual Meeting
Mar 13, 2018 07:02AM Merck (MRK) Says FDA Granted Priority Review to its sBLA for KEYTRUDA for Treatment of Advanced Cervical Cancer
Mar 13, 2018 07:00AM FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) for Treatment of Advanced Cervical Cancer
Mar 7, 2018 05:08PM Merck (MRK), Eisai Co. Enter Strategic Oncology Collaboration for LENVIMA
Mar 7, 2018 05:05PM Eisai Co., Ltd. and Merck Enter Global Strategic Oncology Collaboration for LENVIMA® (lenvatinib mesylate)
Mar 1, 2018 07:10AM Merck (MRK) to Present New Data from Studies of Investigational HIV Therapies Doravirine and MK-8591 at CROI
Mar 1, 2018 07:00AM Merck to Present New Data from Studies of Investigational HIV Therapies Doravirine and MK-8591 at CROI 2018
Feb 23, 2018 07:30AM Merck (MRK) Announces LYNPARZA Received Positive EU CHMP Opinion in Platinum-Sensitive Relapsed Ovarian Cancer
Feb 23, 2018 07:30AM LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion in Platinum-Sensitive Relapsed Ovarian Cancer
Feb 21, 2018 06:13AM Merck (MRK) to Acquire Viralytics for $394 Million
Feb 21, 2018 04:00AM Merck and Viralytics Announce Acquisition Agreement, Expanding Merck’s Leading Immuno-Oncology Pipeline
Feb 15, 2018 08:45AM Merck KGaA, Pfizer (PFE) Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced NSCLC
View More Recent Stories View Older Stories